(R) -Odafosfamide

(R) -Odafosfamide (OBI-3424) is a proagent that is selectively converted by AKR1C3 (aldo-keto reductase 1C3) to a potent DNA-alkylating agent. (R) -Odafosfamide can be used for hepatocellular carcinoma, castrate-resistant prostate cancer, and acute lymphoblastic leukemia (ALL) research[1].

Product Specifications

CAS Number

[2097713-68-1]

Product Name Alternative

OBI-3424; TH-3424; (R) -AST-3424

UNSPSC

12352005

Target

DNA Alkylator/Crosslinker

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/obi-3424.html

Purity

98.52

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O=P(N1CC1)(N2CC2)O[C@@H](C3=CC=C([N+]([O-])=O)C(OC4=CC=CC(C(N(C)C)=O)=C4)=C3)C

Molecular Formula

C21H25N4O6P

Molecular Weight

460.42

References & Citations

[1]Kathryn Evans, et al. OBI-3424, a Novel AKR1C3-Activated Prodrug, Exhibits Potent Efficacy against Preclinical Models of T-ALL. Clin Cancer Res. 2019 Jul 15;25 (14) :4493-4503.